IP Library Granted Patent US 7,846,361
Granted Patent B2
US 7,846,361 · App. 11/781,230 · Granted Dec 7, 2010

Bioabsorbable polymeric composition for a medical device

Assignee: OrbusNeich Medical, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,361
App. No.
11/781,230
Granted
Dec 7, 2010
Kind
B2
Abstract

A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided.

Claims (21)

1. A crystallized bioabsorbable polymer composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers or blocky random copolymers.

2. The crystallized bioabsorbable polymer composition of claim 1 , wherein the polymer composition forms a lactide racemate stereo complex crystal structure between L and D lactide moieties.

3. The crystallized bioabsorbable polymer composition of claim 1 , wherein the polymer composition forms a lactide racemate stereo complex crystal structure, using the moieties comprising:

poly L-lactide with poly D-lactide with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε-caprolactone);

poly D-lactide with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε-caprolactone);

poly L-lactide with poly (D-lactide-co-tri-methylene-carbonate), or with poly(D-lactide-co-ε-caprolactone);

poly L-lactide with poly D-lactide with poly(D-lactide-co-tri-methylene-carbonate), or with poly (D-lactide-co-ε-caprolactone);

poly L-lactide-co-PEG with poly (D-lactide-co-tri-methylene-carbonate), or with poly (D-lactide-co-ε-caprolactone); and

poly D-lactide-co-PEG with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε-caprolactone).

4. The crystallized bioabsorbable polymer composition of claim 1 , wherein the base polymer is from about 70% to about 85% by weight of the composition.

5. The crystallized bioabsorbable polymer composition of claim 1 , wherein the base polymer is 70% by weight of poly L-lactide with 30% by weight of modifying copolymer poly L-lactide-co-TMC.

6. The crystallized bioabsorbable polymer composition of claim 1 , wherein the modifying copolymer is not more than about 40% of the composition.

7. The crystallizable crystallized bioabsorbable polymer composition of claim 1 , wherein a residual monomer concentration of the composition is less than about 0.5%.

8. A bioabsorbable scaffold polymer comprising: a crystallized composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers or blocky random copolymers.

9. The bioabsorbable scaffold polymer of claim 8 , wherein the base polymer is from about 70% to about 80% by weight of the composition.

10. The bioabsorbable scaffold polymer of claim 8 , wherein the base polymer is 70% by weight of poly L-lactide with 30% by weight of modifying copolymer poly L-lactide-co-TMC.

11. The bioabsorbable scaffold polymer of claim 8 , wherein the modifying copolymer is not more than about 40% of the composition.

12. The bioabsorbable scaffold polymer of claim 8 , wherein a residual monomer concentration of the composition is less than about 0.5%.

13. The bioabsorbable scaffold polymer of claim 8 wherein at least one pharmaceutical composition is attached to or incorporated in the polymeric matrix.

14. The bioabsorbable scaffold polymer of claim 8 , wherein at least one pharmaceutical composition may be bound to the polymer matrix by covalent bonds, non-polar bonds as well as ester or similar bioreversible attachment.

15. The bioabsorbable scaffold polymer of claim 8 , wherein the crystallized composition forms a lactide racemate stereo complex crystal structure between L and D lactide moieties.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 15, 2022
From: ORBUSNEICH MEDICAL PTE. LTD.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 060386/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: ORBUSNEICH MEDICAL, INC.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 048043/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2016
From: THATCHER, G. LAWRENCE; COTTONE, ROBERT J.
To: ORBUSNEICH MEDICAL, INC.
Reel/Frame 039641/0300 →
Continuity (3)
Provisional Application 6080793200 · Jul 20, 2006
Provisional Application 6086243300 · Oct 20, 2006
Related Publication 20080118546A1 · May 22, 2008